Chuangsheng Group announces that its humanized anti-VEGFR-2 monoclonal antibody MSB0254 Phase Ib clinical trial has completed the first patient administration

Suzhou, November 25, 2021/PRNewswire/ - Chuangsheng Group (06628.

This study aims to evaluate the safety, tolerability, PK characteristics and anti-tumor efficacy of MSB0254 in a variety of solid tumors, including neuroendocrine tumors and hepatocellular carcinoma, at the recommended doses of phase II clinical trials

MSB0254 is a high-affinity humanized anti-VEGFR-2 monoclonal antibody with an anti-tumor mechanism that inhibits tumor angiogenesis.

About MSB0254

About Chuangsheng Group

Chuangsheng Group is headquartered in Suzhou and has successfully established a global business layout: it has a drug discovery, clinical and translational research center in Suzhou, a process and product development center and a drug production base in Hangzhou, and in Beijing, Shanghai, Guangzhou and the United States Princeton has established clinical development centers, and established foreign cooperation centers in Boston and Los Angeles

For more information about Transcenta Group, please visit the company's website:or LinkedIn account: Transcenta

Forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management regarding future affairs at the time the statement was made

For more information, please contact